Ubicación: Global + English
Global Global Algérie Français Algeria English Angola Português Angola English Argentina Español Argentina English Australia English Austria Deutsch Austria English Azerbaijan English Azerbaijan Русский Bahrain English Bangladesh English Belgium English Belgium Français Belgium Nederlands Brazil Português Brazil English Bulgaria български Bulgaria English Cameroon English Cameroon Français Canada English Canada Français Chile Español Chile English China 中文 China 日本語 China English Colombia Español Colombia English Croatia English Czech Republic Čeština Czech Republic English Denmark English Djibouti English Ecuador Español Ecuador English Egypt English Estonia English Ethiopia English Finland Suomi Finland English France Français France English Georgia English Georgia Русский Germany Deutsch Germany English Ghana English Greece Ελληνικά Greece English Guatemala Español Guatemala English Hong Kong, China English Hong Kong, China 中文 Hungary Magyar Hungary English India English Indonesia English Iraq English Ireland English Italy Italiano Italy English Ivory Coast Français Ivory Coast English Japan 日本語 Japan English Jordan English Kazakhstan Русский Kazakhstan English Kenya English Kuwait English Kyrgyzstan Русский Kyrgyzstan English Latvia English Lithuania English Malaysia English Mauritius English Mauritius français (Maurice) Mexico Español Mexico English Moldova Română Moldova English Mongolia English Morocco English Morocco Français Mozambique Português Mozambique English Netherlands Nederlands Netherlands English New Zealand English Nigeria English Norway English Oman English Pakistan English Paraguay Español Paraguay English Peru Español Peru English Philippines English Poland Polski Poland English Portugal Português Portugal English Qatar English Republic of Korea 한국어 Republic of Korea English Romania Română Romania English Saudi Arabia English Serbia Српски Serbia English Singapore English Slovakia English Slovenia English South Africa English Spain English Spain Español Sri Lanka English Sweden English Switzerland Deutsch Switzerland Français Switzerland Italiano Switzerland English Tanzania English Thailand ไทย Thailand English Togo English Togo Français Tunisia English Tunisia Français Türkiye Türkçe Türkiye English Turkmenistan Русский Turkmenistan English Ukraine Українська Ukraine English United Arab Emirates English United Kingdom English Uruguay Español Uruguay English USA English Uzbekistan English Uzbekistan Русский Vietnam Tiếng Việt Vietnam English

Clinical Evaluation Trial Data Analysis: Methods, Standards, and Regulatory Applications

Clinical evaluation trial data analysis is the systematic process of validating, statistically examining, and interpreting clinical data to demonstrate the safety and performance of medical devices. This guide explains the key data sources, analytical items, statistical methodologies, and international standards—such as ISO 14155:2020 and EU MDR 2017/745—that govern professional clinical evaluation data analysis for regulatory submissions.

Technical Overview

Clinical evaluation trial data analysis refers to the structured collection, validation, statistical processing, and interpretation of data generated during clinical investigations and post-market studies of medical devices and in vitro diagnostic (IVD) products. The objective is to establish objective evidence of clinical safety, performance, and clinical benefit in accordance with the intended purpose claimed by the manufacturer.

The analysis is performed under a documented framework that integrates good clinical practice (GCP) requirements, quality management principles aligned with ISO 13485, and risk management inputs from ISO 14971. Key regulatory and normative references include:

  • ISO 14155:2020 — Clinical investigation of medical devices for human subjects: Good clinical practice
  • EU MDR 2017/745, Annexes XIV and XV — Clinical evaluation and clinical investigation requirements
  • MEDDEV 2.7/1 Revision 4 — Guidance on clinical evaluation of medical devices
  • ISO 20916:2019 — Clinical performance studies using specimens from human subjects (IVDs)
  • ICH E9 — Statistical Principles for Clinical Trials

All analytical activities follow a pre-approved Statistical Analysis Plan (SAP), and the resulting outputs feed directly into the Clinical Evaluation Report (CER), the benefit-risk determination, and regulatory dossiers submitted to notified bodies and competent authorities.

Testing Samples

Clinical Investigation Datasets

Primary datasets collected during prospective clinical investigations conducted in accordance with ISO 14155:2020. These include baseline demographics, device performance measurements, efficacy or effectiveness endpoint observations, adverse event records, and device deficiency logs captured on paper or electronic case report forms (CRF/eCRF).

Literature and Registry Data

Systematically retrieved literature datasets, post-market clinical follow-up (PMCF) survey data, registry datasets, and vigilance or adverse event reporting data. These sources support clinical evaluation pathways based on literature review and post-market evidence rather than, or in addition to, new clinical investigations.

Retrospective and Equivalence Data

Historical datasets from the manufacturer's own earlier device generations, or clinical, biological, and technical data relating to claimed equivalent devices. Equivalence-based datasets require documented justification of comparability in clinical, technical, and biological characteristics before pooled or comparative analysis is performed.

Testing Items

The scope of analytical items in clinical evaluation trial data analysis typically covers the following deliverables:

  • Sample size verification and statistical power justification against the pre-specified assumptions
  • Analysis of primary endpoints, including point estimates, confidence intervals, and hypothesis tests
  • Analysis of secondary and exploratory endpoints
  • Safety analysis covering adverse events, serious adverse events, and adverse device effects as defined in ISO 14155:2020
  • Performance and effectiveness metrics for the stated intended use and intended user profile
  • Subgroup and covariate analyses, where pre-specified in the SAP
  • Missing data assessment, imputation, and sensitivity analyses
  • Benefit-risk synthesis aligned with ISO 14971 risk management outputs
  • Data quality audits: deviation listing, protocol deviation summaries, and data query closure verification

Testing Methods

Data Management and Quality Control

Raw clinical data undergo controlled cleaning: range and logic edit checks, medical coding of adverse events, query issuance and resolution, and a formal database lock before analysis is executed. Data integrity is maintained according to ALCOA+ principles (attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, available), and electronic systems comply with applicable electronic record and signature requirements such as FDA 21 CFR Part 11.

Descriptive and Inferential Statistics

Continuous variables are summarized with means, standard deviations, medians, and interquartile ranges; categorical variables with frequencies and proportions. Inferential methods include t-tests, analysis of variance, chi-square and Fisher exact tests, and non-parametric alternatives such as Wilcoxon rank-sum and Mann-Whitney tests, all reported with two-sided confidence intervals.

Design-Specific Hypothesis Testing

Superiority, equivalence, and non-inferiority trial designs are analyzed with margins pre-justified in the protocol. Non-inferiority analyses confirm that the investigational device is not worse than the comparator by more than the pre-defined margin, with confidence interval approaches preferred over simple p-value reporting.

Survival and Time-to-Event Analysis

For implants and long-use devices, Kaplan-Meier survival curves, log-rank tests, and Cox proportional hazards models estimate device-related event rates and hazard ratios over the follow-up period.

Diagnostic Accuracy Analysis

For IVD clinical performance studies conducted under ISO 20916:2019, diagnostic accuracy items include sensitivity, specificity, positive predictive value, negative predictive value, and receiver operating characteristic (ROC) curve analysis with area under the curve estimation, referenced against an established comparative method.

Population Set Definitions and Sensitivity Analysis

Analyses are performed on the full analysis set (intention-to-treat principle) and the per-protocol set, with pre-defined conventions for protocol deviations. Missing data are handled via documented methods such as last observation carried forward, multiple imputation, or worst-case analysis, supported by sensitivity analyses to confirm the robustness of conclusions. All computations are executed in validated statistical software environments with version-controlled programs and reproducible outputs.

Applications

Clinical evaluation trial data analysis supports a broad range of regulatory and engineering purposes:

  • Clinical Evaluation Reports (CER) for CE technical documentation under EU MDR 2017/745
  • Clinical evidence packages for regulatory submissions, including 510(k), De Novo, and premarket approval pathways in the United States
  • Registration dossiers for national market authorization, including NMPA submissions in China
  • Post-market clinical follow-up (PMCF) evaluation plans and reports
  • Updates to the ISO 14971 risk management file, including benefit-risk ratio reassessment
  • Justification of design changes, expanded indications, and new clinical claims
  • Independent statistical review by accredited third-party laboratories and notified bodies

FAQ

What standards govern clinical evaluation trial data analysis?

The core references are ISO 14155:2020 for clinical investigation conduct, ISO 20916:2019 for IVD clinical performance studies, EU MDR 2017/745 Annexes XIV and XV, MEDDEV 2.7/1 Revision 4 for clinical evaluation methodology, ICH E9 for statistical principles, and ISO 14971 for benefit-risk integration.

How is the sample size for a clinical investigation determined?

Sample size is calculated from the primary endpoint, the null and alternative hypotheses, the significance level (typically 0.05), the target statistical power (typically 80% or 90%), expected event rates or effect sizes from literature or pilot data, and the anticipated dropout rate. The calculation is documented in the protocol and independently verified during data analysis.

What is the difference between intention-to-treat and per-protocol analysis?

The full analysis set follows the intention-to-treat principle and includes all enrolled subjects with any outcome data, minimizing attrition bias. The per-protocol set includes only subjects who completed the study without major protocol deviations. Comparing both analyses demonstrates the robustness of the conclusions.

How are missing data handled in clinical evaluation analysis?

Missing data patterns are first characterized and classified as missing completely at random, missing at random, or missing not at random. Documented strategies include available-case analysis, multiple imputation, and sensitivity analyses such as worst-case imputation to confirm that findings are not materially affected.

What deliverables are produced at the end of the analysis?

Typical deliverables include the validated analysis datasets, the executed Statistical Analysis Plan, statistical tables, listings, and figures (TLFs), the clinical study report sections consistent with ISO 14155:2020, and summarized evidence ready for integration into the Clinical Evaluation Report.

Can literature data alone support a clinical evaluation?

Where sufficient quality and relevance exist, a systematic literature review combined with post-market data, including PMCF results and vigilance information, can support the clinical evaluation without a new clinical investigation. The sufficiency of this pathway depends on the device classification, the level of clinical evidence required, and the applicable regulatory framework.

Why Choose ZKGX?

  • State-of-the-art analytical equipment
  • Highly qualified scientific team
  • Fast turnaround time
  • Competitive pricing